NEW YORK, Jan. 12, 2012 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation will host the 6th Annual Drug Discovery for Neurodegeneration Conference: An Intensive Course on Translating Research into Drugs on February 12-14, 2012, at the Princeton Club in New York City. The purpose of the conference is to educate scientists on the process of translating basic research into novel therapies, with a focus on Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. This meeting attracts over 140 academic, industry and government scientists from around the world.
The conference is organized around six sub-topics: Basics of Medicinal Chemistry; Early Phases of Drug Discovery; Pre-Clinical Proof-of-Concept & Development; What's Druggable: Designing Drugs for CNS Target Classes;Commercialization Strategies: Developing Science into Products; and Resources and Services for Advancing Drug Discovery and will include lectures from twenty-eight international leaders in the field of neurodegenerative disease drug discovery.
The ADDF is pleased to announce that this year's conference will feature Dr. Christopher A. Lipinski, author of the "Rule of Five," as plenary speaker.
This CME accredited conference is organized and sponsored by the ADDF. It is also supported by a conference grant: U13-AG031125 from the National Institute on Aging. Additional sponsors include the Michael J. Fox Foundation, The National Multiple Sclerosis Society, JSW Life Sciences, MS Fast Forward, BioFocus and the Forest Research Institute.
FOR JOURNALISTS,if you would like more information on Alzheimer's disease and drug discovery, to speak with Dr. Howard Fillit, Executive Director, ADDF, or if you would like to receive press credentials to attend the conference, please contact Filomena Machleder at 212-901-8004 or email@example.com.
FOR CONFERENCE DETAILS AND TO REGISTER, please visit the conference website. Group discounts are available.
TO CO-SPONSOR OR EXHIBIT, please contact Filomena Machleder at firstname.lastname@example.org.
About the Alzheimer's Drug Discovery Foundation
The Alzheimer's Drug Discovery Foundation (ADDF) is the only non-profit organization whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $51 million to fund over 370 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information about the ADDF, please visit www.alzdiscovery.org.
SOURCE Alzheimer's Drug Discovery Foundation